Like many women, Claudia knew something wasn’t quite right when she began to experience an unusual pain in her pelvic area and excessive sweating while at work. Later in the night, she ended up in the hospital with emergency surgery, … Read more
A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.
In a new article in JAMA Oncology, the … Read more
Disease control in two-thirds of patients treated with bispecific antibody.
By Charles Bankhead
An investigational drug that combines PD-1/L1 inhibition and T-cell stimulation led to disease control in two-thirds of patients with unresectable advanced solid malignancies, a preliminary clinical study … Read more
Does a pharmaceutical company have a moral obligation to acknowledge my participation with an ongoing supply of the product that I helped test?
When I learned this summer that the clinical trial of the cancer drug that … Read more
By Andrew D. Bowser
However, trials investigating retreatment are underway, so this recommendation may change.
The guidelines, from … Read more
KSQ Therapeutics is hoping to provide hope for ovarian and breast cancer patients that have developed a resistance to drugs and those who don’t respond at all by developing a drug that may be able to boost the effectiveness of … Read more
By Robert Dillard
A new drug developed to treat cancers with an altered BRAF gene has shown efficacy in an early patient trial, according to a study presented at the 32nd EORTC-NCI-AACR  Symposium on Molecular Targets and Cancer Therapeutics, … Read more
By Anne Harding
New findings debunk the conventional wisdom that Black cancer patients are less likely to agree to participate in clinical trials.
Overall, 55% of patients offered trial participation agreed to enroll, and white and Black patients agreed to … Read more
By Angus Liu
Many oncology researchers and practitioners scrutinize genetic alterations in cancer, but they either focus on one particular tumor type or one mutation that occurs across tumors. A large-scale study focusing on precision medicine in cancer is now … Read more
CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches over 1 million patients, has named the winners of its Third Annual Ovarian Cancer Heroes® awards program. The virtual celebration will be held Friday, … Read more
By Savannah Demko
Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.
“Preclinical studies suggest the potential for synergy between … Read more
Researchers have seen promising results by injecting dog and mouse tumors with the cowpea mosaic virus. Now they’re aiming for a human trial.
By Daniel Oberhaus
Researchers are optimistic that data from a first-in-human clinical trial of Bayer’s ATR-inhibiting agent, BAY-1895344, may pave the way for a new class of precision oncology treatments for patients with certain DNA damage response (DDR) defects in their tumors.
The … Read more
By Matthew Fowler
xCures recently announced that the FDA granted its IND immediate Expanded Access Program for the ERK inhibitor ulixertinib to treat patients with MAPK pathway aberrant cancer.
The FDA granted the investigational new drug application for the ERK
By Liam Drew
PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate and other types of cancer. To develop these drugs, researchers supported by Cancer Research UK had to decipher how blocking DNA repair could expose a weak … Read more